Protective effect of Yi-Qi-Huo-Xue Decoction against ischemic heart disease by regulating cardiac lipid metabolism.
10.1016/S1875-5364(20)60018-8
- Author:
Fang-He LI
1
;
Xiao-Lou HUANG
2
;
Hui WANG
3
;
Shu-Wen GUO
4
,
5
;
Ping LI
5
,
6
Author Information
1. The Third Affiliated Hospital, Beijing University of Chinese Medicine, Beijing 100029, China; School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
2. College of Acupuncture and Orthopedics, Guizhou University of Traditional Chinese Medicine, Guiyang 550025, China.
3. School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
4. Fangshan Hospital, Beijing University of Chinese Medicine, Beijing 102400, China. Electronic address: guo1163@
5. com.
6. The Third Affiliated Hospital, Beijing University of Chinese Medicine, Beijing 100029, China. Electronic address: pearll2008@
- Publication Type:Journal Article
- Keywords:
AMPK-dependent pathway;
Fatty acid oxidation;
Ischemic heart disease;
Lipid metabolism;
Yi-Qi-Huo-Xue Decoction
- From:
Chinese Journal of Natural Medicines (English Ed.)
2020;18(10):779-792
- CountryChina
- Language:English
-
Abstract:
Yi-Qi-Huo-Xue Decoction (YQHX) is the recombination of Dang-Gui-Bu-Xue Decoction (DBD), which is one of the well-known traditional Chinese Medicine (TCM) prescription, and has long been shown to have significant protective effects against myocardial ischemic injury. In previous studies, we found that YQHX could regulate lipid and glucose metabolism, promote angiogenesis, attenuate inflammatory response, and ameliorate left ventricular function in myocardial ischemia rat models. However, the underlying mechanism of how YQHX involves in lipid metabolism remains unclear so far. In this study, the underlying mechanism of YQHX in lipid metabolism disorders was elucidated in a myocardial ischemia rat model and a hypoxia-induced H9c2 cell injury model. YQHX (8.2 g·kg) and positive-control drug trimetazidine (10 mg·kg) were administered daily on the second day after left anterior descending (LAD) operation. At 7 days and 28 days after surgery, changes of cardiac morphology, structure, and function were evaluated by H&E staining and echocardiography, respectively. The plasma lipid levels and mitochondrial ATP content were also evaluated. Western blot and RT-PCR were used to determine the protein and mRNA expressions of AMPK, PGC-1α, CPT-1α, and PPARα. YQHX improved cardiac function and ameliorated lipid metabolism disorders. Furthermore, YQHX increased the expression of p-AMPK, PGC-1α, and CPT-1α without changing PPARα in ischemic rat myocardium. In vitro, YQHX activated the protein and mRNA expression of PGC-1α, CPT-1α, and PPARα in hypoxia-induced H9c2 cells injury, whereas AMPK inhibitor Compound c blocked the effects of YQHX. Taken together, the results suggest that YQHX reduces lipid metabolism disorders in myocardial ischemia via the AMPK-dependent signaling pathway.
